COMPANY OVERVIEW

BP8 is a plant-focused biotechnology company that produces foods and products which deliver Traditional Chinese Medicine (“TCM”) based health outcomes. The Company business operations are focused on the cultivation and acquisition of seaweed in Indonesia for on-sale into the Indonesian and Chinese markets. 

The Company also has research & development operations which focus on the production, and commercialisation of seaweed and sea plants to produce sustainable plant-based foods and nutraceutical and pharmaceutical ingredients for utilisation in the food, nutrition, healthcare, health supplements, cosmetics and personal care industries.

The Company’s key markets are Indonesia, Singapore and South Korea with plans to expand further into Southeast Asia and also into Australia.

The Offer:

• BP8 is undertaking a two tranche placement of up to 550,000,000 ordinary shares in aggregate at A$0.002 per share (Placement Shares) to raise up to A$1,100,000 (before costs). 
• Tranche 1 comprises up to 250,000,000 shares and will be issued as follows:
1. up to 146,000,000 ordinary shares pursuant to the Company’s share issuing capacity under ASX Listing Rule 7.1; and
2. up to 104,000,000 ordinary shares pursuant to the Company’s share issuing capacity under ASX Listing Rule 7.1A.
• Tranche 2 comprises up to 300,000,000 shares plus any balance of the Tranche 1 allocation of shares that were not issued. The Tranche 2 shares will be issued post the 2025 AGM in November, subject to shareholders approving the issue of those shares at that meeting. Tranche 2 includes an application for 25,000,000 Placement Shares to raise $50,000 from entities associated with Company Director, Francesco Cannavo, which will be issued subject to approval for the purposes of ASX Listing Rule 10.11.
• Pending BP8 shareholder approval at the 2025 AGM, one (1) free attaching option will be issued for each two (2) Placement Shares allotted (“Option”). The Options will expire 2 years from their issue date and have an exercise price A$0.004. 

THIS OFFER IS FOR SOPHISTICATED AND PROFESSIONAL INVESTORS ONLY AS ASCRIBED UNDER SECTIONS 708(8), 708(10) AND 708(11) OF THE CORPORATIONS ACT 2001

For more information please contact: 

Naveed Hussain, Senior Corporate Advisor,  Novus Capital Limited 

Mobile +61 410 478 786 E: naveed.hussain@novuscapital.com.au

Click to download the Term Sheet